drugset / Trial / NCT01755416

Liraglutide Versus Insulin Mono-therapy in the Closed Loop Setting

NCT01755416

RandomizedCrossoverOpen-labelTreatment

Summary

Hypothesis: In type 1 diabetes mellitus, in the setting of a closed loop glucose control system: adjunctive therapy with Liraglutide will afford better post-prandial glycemic excursions than insulin mono-therapy. Specific Aim: To determine if post-prandial glucose excursions are lowered with the addition of Liraglutide compared to insulin mono-therapy. Study Design: This is a randomized open labeled crossover design trial comparing adjuvant Liraglutide and insulin Vs. insulin mono-therapy using the ePID closed-loop system for insulin delivery.

Timeline

Start
2013-01
Primary completion
2015-01
Completion
2015-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Liraglutide Peptide 1.2 mg Subcutaneous
Comparator Insulin Protein / enzyme biologic